相关实验视频

Updated: Jun 28, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

在复发性或耐火性外围T细胞淋巴瘤的新药和治疗方案:最新更新从2023年ASH年会的最新更新

Huageng Huang¹, Wei Zhang², Xinyi Deng³

¹Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.

Experimental hematology & oncology

|April 22, 2024

概括

针对复发或耐药的周围T细胞淋巴瘤 (PTCL) 正在出现创新的治疗方法,为更好的结果提供了希望. 最近的进展针对特定的途径,并利用新的组合来改善患者的存活率.

科学领域:

血液学血液学血液学
在瘤学瘤学.
免疫学免疫学免疫学

背景情况:

周围T细胞淋巴瘤 (PTCL) 代表了一组不同的血液癌症,预后通常不好.
目前针对复发性或耐火性 (R/R) PTCL的治疗策略具有有限的疗效,且没有进展的生存率很短.

关键词:

临床研究是临床研究.周围T细胞淋巴瘤耐火的耐火的耐火的复发复发的情况

更多相关视频

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.